



05-08-03

GP 1626

**EXPRESS MAIL CERTIFICATE**

"Express Mail" Label No. : EV 130 844 745 US  
Serial No. : 10/091,609  
Applicant(s) : Adnan M.M. Mjalli et al.  
Filing Date : March 5, 2002  
Title: : Benzimidazole Derivatives As Therapeutic Agents  
Examiner : Laura Stockton  
Group Art Unit : 1626  
Type of Document(s) : Express Mail Certificate;  
Transmittal Form;  
Election and Response; and  
Return Postcard

**RECEIVED**  
MAY 09 2003  
TECH CENTER 1600/2900

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Mail Stop \_\_\_\_\_, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Carol McCabe (signature)  
Carol McCabe

*Date Mailed: May 7, 2003*

Please type a plus sign (+) inside this box →



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number



# TRANSMITTAL FORM

*to be used for all correspondence after initial filing)*

Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli et al.
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	41305-271622

Total Number of Items in This Submission (including Transmittal Form)	4
---	---

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached Check _____ <input checked="" type="checkbox"/> Election and Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Express Mail Certificate – EV 130 844 745 US Transmittal Form Return Postcard
Remarks		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Samuel B. Rollins, Esq., Kilpatrick Stockton LLP Reg. No. 52,180
Signature	<i>Samuel B. Rollins</i>
Date	May 6, 2003

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service's first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:			
Typed or printed name		SENT VIA EXPRESS MAIL	
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.